Leerink Partners analyst Jonathan Chang has maintained their bullish stance on IMTX stock, giving a Buy rating on November 6. Jonathan ...

Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with significant responses in metastatic melanoma patients and ...

The market expects Immatics (IMTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen.

In this article, we are going to take a look at where Immatics N.V. (NASDAQ:IMTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid ...

https://www.tipranks.com/news/the-fly/argenx-price-target-raised-to-660-from-540-at-truist-2 Immatics (IMTX) has released an update. Immatics has reported promising ...

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T ...

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits ...